Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

hsCRP May Be Viable Blood Biomarker for mTBI

J Head Trauma Rehabil; ePub 2018 Nov 28; Shetty, et al

High sensitivity C-reactive protein (hsCRP) may be a viable addition to acute and longitudinal biomarker panels for diagnosis and prognosis of mild traumatic brain injury (mTBI), according to a recent retrospective cohort study. In a neurology department of high-volume tertiary orthopedic hospital, researchers evaluated individuals diagnosed with mTBI (n=311, age 21 ± 12 years, 53% female). Continuous hsCRP levels were transformed into quartiles, as defined by <0.200 mg/L for quartile 1 (Q1); 0.200 to 0.415 mg/L for quartile 2 (Q2); 0.415 to 1.100 mg/L for quartile 3 (Q3); and >1.100 mg/L for quartile 4 (Q4). They found:

  • Mean hsCRP was elevated in the cohort of individuals who presented within 1 week of injury and was found to significantly decrease between the first visit and 4 weeks post-injury.
  • Initial hsCRP level was positively correlated with age (r = 0.163), and age significantly increased between quartiles.
  • Patients with increased age (odds ratio: 3.48) and those who endorsed headache (odds ratio: 3.48) or fatigue (odds ratio: 2.16) were significantly associated with increased risk of having an hsCRP level in Q4.


Shetty T, Cogsil T, Dalal A, et al. High-sensitivity C-reactive protein: Retrospective study of potential blood biomarker of inflammation in acute mild traumatic brain injury. [Published online ahead of print November 28, 2018]. J Head Trauma Rehabil. doi:10.1097/HTR.0000000000000450.